Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 08 February, 2013 and appeared in  DietObesityWomen's HealthIssue 663

Reducing Risk of Diabetes in Pregnancy with a Supplement

A nutritional supplement may help protect women at risk for gestational diabetes....

Advertisement

Previous studies have shown that inositol supplements may help restore fertility in polycystic ovary syndrome, but this is the first evidence that the supplement called myo-inositol may reduce the number of cases of gestational diabetes.

Women who are overweight or obese or have a family history of diabetes are at risk for gestational diabetes, which affects up to 10 percent of pregnancies in the U.S., according to the Centers for Disease Control and Prevention.

Mothers with the condition have trouble dealing with carbohydrates leading to high blood sugar.

Lead author, Dr. Rosario D'Anna, of the Department of Obstetrics at University Hospital in Messina, Italy, added that, "Undiagnosed and untreated gestational diabetes can cause large-for-gestational-stage babies, which may lead to delivery complications."

The researchers selected 220 pregnant women with a family history of type 2 diabetes. Half the women were given two grams of myo-inositol supplements twice a day along with the recommended amount of folic acid, a supplement recommended for all pregnant women. The other women were given only folic acid, from the end of the first trimester throughout pregnancy.

A bottle of 60 650-milligram myo-inositol supplements, available in the U.S. without a prescription, costs about $10. The compound is also found in fruits, nuts, grains, and meats, but not at very high levels.

Of the women who took myo-inositol, six percent developed gestational diabetes, compared to 15 percent of the women who only took folic acid, according to the study

None of the babies in the myo-inositol group met criteria for being overweight, but seven babies in the non-supplement group did, weighing more than eight pounds, 13 ounces.

Dr. Donald Coustan of the Division of Maternal-Fetal Medicine at Women and Infants Hospital of Rhode Island in Providence, who was not part of the study, added that, despite these positive findings, researchers don't know how the supplement works or if it is safe. "The results are promising, but we would need a larger trial and a broader group of women before recommending this supplement."

Diabetes Care, March 21, 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2013 and appeared in  DietObesityWomen's HealthIssue 663

Past five issues: Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Guy Pupp, DPM, FACFAS

Category: Diabetic Foot
Credits:
 1.0
Search Articles On Diabetes In Control